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After the publication \[[@CR1]\] the authors report corrections for Table [@CR1], for the headers of columns 5 and 7, which should read as follows: Column 5 Header: *P*-value for pCR, T vs Other Arms in HR^+^, and Column 7 Header: *P*-value for pCR, T vs Other Arms in HR^--^.

The correct version of the table can be found below: Table 3NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR statusTreatment arms,\
*n* = 42 each armTotal pCR*P-value* for pCR T vs Other Arms in all patients^a^pCR HR^+^*P-value* for pCR T vs Other Arms in HR^+\ b^pCR HR^−^*P-value* for pCR T vs Other Arms in HR^−\ b^*P-value* HR^+^ vs HR^−^Arm 1 (T)16/41 (39.0%)NA8/27 (29.6%)NA8/14 (57.1%)NA0.11Arm 2 (N)14/42 (33.3%)0.638/29 (27.6%)16/13 (46.2%)0.710.30Arm 3 (T plus N)21/42 (50%)0.227/23 (30.4%)114/19 (73.7%)0.460.01All arms51/126 (40%)23/79 (29%)28/46 (61%)0.001Abbreviations: T, trastuzumab; N, neratinib^a^CMH test stratified for the time period the patients were randomized to the study (prior/after the addition of Arm 3)^b^Fisher's exact test
